Acetylcholine Release Inhibitors
"Acetylcholine Release Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that block release of the neurotransmitter ACETYLCHOLINE.
| Descriptor ID |
D065087
|
| MeSH Number(s) |
D27.505.519.562.061 D27.505.519.625.120.069 D27.505.696.577.120.069
|
| Concept/Terms |
Acetylcholine Release Inhibitors- Acetylcholine Release Inhibitors
- Inhibitors, Acetylcholine Release
- Acetylcholine Release Antagonists
- Antagonists, Acetylcholine Release
- Acetylcholine Release Blockers
- Blockers, Acetylcholine Release
- Release Blockers, Acetylcholine
|
Below are MeSH descriptors whose meaning is more general than "Acetylcholine Release Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Acetylcholine Release Inhibitors".
This graph shows the total number of publications written about "Acetylcholine Release Inhibitors" by people in this website by year, and whether "Acetylcholine Release Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Acetylcholine Release Inhibitors" by people in Profiles.
-
Loeb LM, Amorim RP, Mazzacoratti MDGN, Scorza FA, Peres MFP. Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison. Arq Neuropsiquiatr. 2018 10; 76(10):663-667.
-
Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, Villa G, Shah N, Tepper S, Dodick D. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018 Jul; 21(7):666-675.
-
Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017 Nov 28; 89(22):2245-2253.
-
O'Connell Ferster AP, Sataloff RT, Shewokis PA, Hu A. Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study. J Voice. 2018 Jul; 32(4):479-483.
-
Francisco GE, Bandari DS, Bavikatte G, Jost WH, Adams AM, Largent J, Esquenazi A. Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics. J Rehabil Med. 2017 Aug 31; 49(8):659-666.
-
Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Esquenazi A, Graham GD, McGuire JR, Odderson I. OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process. PM R. 2017 02; 9(2):136-148.